Provided by Tiger Trade Technology Pte. Ltd.

Immunome Inc.

25.66
-0.4600-1.76%
Volume:148.66K
Turnover:3.82M
Market Cap:2.91B
PE:-10.33
High:26.08
Open:25.69
Low:25.56
Close:26.12
52wk High:30.06
52wk Low:8.93
Shares:113.58M
Float Shares:108.11M
Volume Ratio:0.39
T/O Rate:0.14%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4851
EPS(LYR):-2.4315
ROE:-64.03%
ROA:-37.78%
PB:5.55
PE(LYR):-10.55

Loading ...

Immunome Begins Phase 1 Trial Dosing of Therapy for Advanced Solid Tumors

MT Newswires Live
·
Jul 20

Immunome announces first patient dosed in Phase 1 IM-3050 trial

TIPRANKS
·
Jul 20

Immunome Notifies Availability of Press Release

Reuters
·
Jul 20

Immunome - Phase 1 Trial to Evaluate Safety and Preliminary Activity of Im-3050

THOMSON REUTERS
·
Jul 20

Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating Im-3050, an Fap-targeted Radioligand Therapy, in Patients with Fap-expressing Advanced Solid Tumors

THOMSON REUTERS
·
Jul 20

Immunome (IMNM) NDA Acceptance Puts Valuation Back In Focus

Simply Wall St.
·
Jul 18

Why Immunome (IMNM) Is Down 8.2% After FDA Accepts Varegacestat NDA With Strong Phase 3 Data

Simply Wall St.
·
Jul 17

Analysts Are Bullish on These Healthcare Stocks: Immunome (IMNM), COMPASS Pathways (CMPS)

TIPRANKS
·
Jul 11

Immunome Chief Business Officer Horn Kinney Disposes of 1,092 Common Shares Worth $27,300

Reuters
·
Jul 10

Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS) and Immunome (IMNM)

TIPRANKS
·
Jul 09

Immunome’s NDA for varegacestat in desmoid tumors accepted by FDA

TIPRANKS
·
Jul 08

Immunome Flags Press Release on FDA Acceptance of Varegacestat NDA for Desmoid Tumors

Reuters
·
Jul 08

Immunome - Pdufa Target Action Date for Varegacestat Set for April 28, 2027

THOMSON REUTERS
·
Jul 08

Immunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid Tumors

THOMSON REUTERS
·
Jul 08

Immunome CMO Robert Lechleider Sells USD 1.27 Million in Common Shares

Reuters
·
Jul 08

Immunome Grants 344,000 Inducement Stock Options Priced at $21.49 Per Share

Reuters
·
Jul 08

Immunome Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Jul 08

Immunome Director Isaac Barchas Disposes of 201,050 Common Shares Worth $4.4 Million

Reuters
·
Jul 03

Analyst Brian Cheng Initiates Buy on Immunome, Citing Differentiated Pipeline and Compelling Risk‑Reward Profile

TIPRANKS
·
Jun 30

Immunome Chief Medical Officer Robert Lechleider Disposes of 55,000 Common Shares Worth $1.09 Million

Reuters
·
Jun 30